Skip to main content

Table 4 Association between clinical characteristics and presymptomatic COVID-19 patients in our cohort

From: The prevalence and clinical significance of Presymptomatic COVID-19 patients: how we can be one step ahead in mitigating a deadly pandemic

Characteristics n (%) Presymptomatic P value
Yes (%) No (%)
Gender Female 52 (26.1) 18 (34.6) 34 (65.4) 0.019*
Male 147 (73.9) 25 (17.0) 122 (83.0)
Nationality Local 140 (70.4) 29 (20.7) 111 (79.3%) 0.707
Foreigner 59 (29.6) 14 (23.7) 45 (76.3)
Highest MEWS; 0 2 (1.0) 1 (50.0) 1 (50.0) 0.023*
1 157 (79.3) 34 (21.7) 123 (78.3)
2 32 (16.2) 5 (15.6) 27 (84.4)
3 6 (3.0) 3 (50.0) 3 (50.0)
4 1 (0.5) 0 (0) 1 (100.0)
Category after re-evaluation 1 93 (46.7) 0 (0) 93 (100.0)
2A 59 (29.6) 27 (45.8) 32 (54.2)
2B 20 (10.1) 8 (40.0) 12 (60.0)
3A 20 (10.1) 5 (25.0) 15 (75.0)
3B 2 (1.0) 2 (100.0) 0 (0)
4A 2 (1.0) 1 (50.0) 1 (50.0)
4B 1 (0.5) 0 (0) 1 (100.0)
5 2 (1.0) 0 (0) 2 (100.0)
Cigarette smoking Yes 15 (12.1) 2 (13.3) 13 (86.7) 0.359
Reformed 8 (6.4) 1 (12.5) 7 (87.5)
No 101 (81.5) 24 (23.8) 77 (76.2)
Blood abnormalities on admission Yes 50 (25.1) 10 (20.0) 40 (80.0) 0.817
No 149 (74.9) 33 (22.1) 116 (77.9)
Blood abnormalities during stay Yes 55 (27.6) 11 (20.0) 44 (80.0) 0.485
No 144 (72.4) 22 (22.2) 112 (71.8)
Abnormal blood indices CBC
RP
LFT
6 (3.0)**
20 (10.1)**
55 (27.6)**
2 (33.3)
4 (20.0)
11 (20.0)
4 (66.7)
16 (80.0)
44 (80.0)
0.442
0.487
0.119
X-ray changes Yes 30 (15.1) 10 (33.3) 20 (66.7) 0.126
No 169 (84.9) 33 (19.5) 136 (80.5)
CT thorax performed Yes 44 (22.1) 8 (18.6) 36 (23.1) 0.748
No 155 (77.9) 35 (81.4) 120 (76.9)
Treatment Yes 45 (22.6)** 20 (44.4) 25 (55.6) < 0.001*
Negative PCR based on day of illness Mean 16.42 Days 17 Days 16 Days 0.293
  1. *Fisher exact test with level of significance at < 0.05
  2. **Percentages depicting total number of abnormal readings/treated patients only (n = 199)